The Two Types of Compounding Pharmacies
The FDA recognizes two distinct categories of compounding pharmacies under the Drug Quality and Security Act (DQSA) of 2013. Understanding the difference is essential for anyone sourcing peptides through legitimate pharmacy channels.
503A Compounding Pharmacies
Section 503A pharmacies are traditional compounding pharmacies that:
- Prepare medications based on individual patient prescriptions
- Must have a valid patient-specific prescription before compounding
- Are primarily regulated by state boards of pharmacy
- Cannot compound large batches in advance (with limited exceptions)
- Must comply with USP 795 (non-sterile) and USP 797 (sterile) standards
For peptide buyers: 503A pharmacies are the most common path for obtaining compounded peptides with a prescription. Your doctor writes a prescription, and the pharmacy compounds it specifically for you.
503B Outsourcing Facilities
Section 503B facilities are a newer category that:
- Can compound without individual prescriptions
- Produce larger batches for office use by healthcare practitioners
- Are registered with and inspected by the FDA
- Must follow current Good Manufacturing Practices (cGMP)
- Report adverse events directly to the FDA
For peptide buyers: 503B facilities typically supply clinics and medical offices rather than individual patients. Your doctor's clinic may purchase peptides from a 503B facility to administer in-office.
Key Differences at a Glance
| Feature | 503A | 503B |
|---|---|---|
| Prescription required | Yes (patient-specific) | No (can sell to practitioners) |
| Primary regulator | State board of pharmacy | FDA |
| Batch compounding | Limited | Yes |
| cGMP required | No (USP standards) | Yes |
| FDA inspection | Not routine | Regular |
Which Is Better?
Neither is inherently "better" — they serve different purposes. 503B facilities offer more regulatory oversight and standardized manufacturing, while 503A pharmacies offer personalized compounding and may be more accessible for individual patients.
Some pharmacies hold both designations, which demonstrates capability and compliance at both levels. When evaluating a pharmacy, check their current FDA inspection history and state licensing status — the regulatory landscape shifts frequently.
Important: Tirzepatide Compounding Is No Longer Legal
The FDA declared the tirzepatide (Mounjaro/Zepbound) shortage resolved as of October 2024. Enforcement discretion for compounding pharmacies — both 503A and 503B — ended in March 2025, and a federal court upheld the FDA's decision in May 2025.
What this means: Standard compounded tirzepatide is no longer legally permitted from either type of pharmacy. Some compounders continue to offer modified versions (different dosage, added ingredients like B12, or altered delivery method) under a narrow legal argument — but this remains a gray area under active regulatory pressure.
Semaglutide (Ozempic/Wegovy) was removed from the FDA shortage list on February 21, 2025. While broad shortage-based compounding has ended, some 503A pharmacies continue patient-specific compounding under a narrower legal framework. The situation is actively being litigated. Check [FDA.gov](https://www.accessdata.fda.gov/scripts/drugshortages/) and confirm availability directly with your pharmacy.